Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
AstraZeneca Files COVID Antibody in Japan, Seeks Special Approval
AstraZeneca said on June 9 that it has submitted a new drug application in Japan for its long-acting COVID-19 antibody cocktail AZD7442, known as Evusheld overseas, seeking special approval for its use in both prophylactic and therapeutic settings. AZD7442 is…
To read the full story
Related Article
- AZ’s Evusheld Gets Label Update on Repeat Dosing
February 21, 2023
- Japan to Supply AstraZeneca’s Evusheld Only for COVID-19 Prevention
September 2, 2022
- Japan Approves AstraZeneca’s COVID-19 Cocktail Therapy Evusheld
August 30, 2022
- AstraZeneca’s COVID Cocktail in Line for Approval, Comirnaty Booster for Ages 5-11
August 30, 2022
- AstraZeneca’s COVID Cocktail Up for Aug. 29 PAFSC Session; Comirnaty Pediatric Booster Too
August 23, 2022
- Japan Mulls Securing AstraZeneca COVID Cocktail If Approved: Minister
June 13, 2022
- AZ’s COVID-19 Drug to Be Reviewed with Priority if Filed in Japan: Senior Vice Minister
December 22, 2021
BUSINESS
- Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
- ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- AstraZeneca Launches Japan Registry Study of Imfinzi in Limited-Stage SCLC
February 18, 2026
- Asahi Kasei Gets Global Rights to Alchemedicine’s Lead Compounds
February 18, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…